| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Product Name | Acalabrutinib |
|---|
| Description | Acalabrutinib (ACP-196) is an orally available, selective irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It is a second generation BTK inhibitor with improved pharmacological properties with better plasma exposure, oral absorption and shorter half-life. It prevents the activation of B-cell antigen receptor (BCR) signaling pathway, thus preventing B-cell activation and BTK mediated activation of downstream survival pathways. MW: 465.52. Purity ≥98% by HPLC |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide; ACP-196 |
|---|
| Gene, Accession, CAS # | CAS: 1420477-60-6 |
|---|
| Catalog # | B1193-5 |
|---|
| Price | |
|---|
| Order / More Info | Acalabrutinib from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|